The Peptides That Run Fertility, and the One Being Oversold

GLP-1 drugs can bring back ovulation in women with PCOS. That is not the same as a fertility drug, and the difference can end in a surprise pregnancy on a medication you should stop first.

Peptides in Women’s Health · Part 3 of 7

Fertility medicine already runs on peptides. One of them is being oversold, and the mislabel has real consequences.

Fertility medicine already runs on peptides. The drugs that suppress or trigger ovulation in IVF, the hormones that grow the eggs, the brain signal that starts the whole cycle, all peptides. So when a weight-loss peptide starts bringing back ovulation in women who were not ovulating, it gets called a fertility drug. It is not one. And that mislabel can end in a surprise pregnancy on a medication that should be stopped before conception.

Polycystic ovary syndrome, or PCOS, is the most common hormonal cause of infertility. Many women with PCOS carry extra weight and insulin resistance, and that combination disrupts ovulation. GLP-1 drugs like semaglutide and liraglutide lower weight and improve insulin handling. When they do, ovulation can return. That is real, and for some women it is welcome. But improving the conditions that block ovulation is not the same as a drug designed to make you pregnant.

Here is what gets lost. A woman told her PCOS makes pregnancy hard, who then starts ovulating again on a GLP-1, can conceive without expecting to, while taking a drug not recommended in pregnancy. The fertility win and the medication risk arrive together. That is the part the marketing skips.

Paid subscribers continue below.